Try Alerts Free   |   Login
Health Care › BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

KYMR Price Correlated With Financials For Kymera Therapeutics

Free historical financial statements for Kymera Therapeutics Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 9 quarters since 2020. Compare with KYMR stock chart to see long term trends.

KYMR Stock Compared to Quarterly

KYMR Income Statement

Revenue, Net:9551000
Revenue Per Share:0.1741
Selling, General & Admin Expense:10556000
Research & Development Expense:43877000
Total Operating Expenses:54433000
Operating Income:-44882000
Income Taxes:0
Net Income:-43002000
Earnings Per Share, Basic:-0.79
Shares Outstanding, Basic Avg:54864727

KYMR Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:767000
Net Cash from Operations:-34269000
Net Cash from Operations Per Share:-0.6246
Net Cash from Financing Activities:150497000
Property, Plant & Equipment Purchases:1246000
Net Cash from Investing Activities:-37481000
Net Change in Cash & Equivalents:78747000

KYMR Balance Sheet

Cash and Cash Equivalents:161774000
Total Current Assets:494022000
Property, Plant & Equipment, Net:12569000
Total Assets:638472000
Accounts Payable:6327000
Total Short-Term Liabilities:91124000
Total Liabilities:125587000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
BVF PARTNERS L P/IL   Director
41,007 sh at $31
$1,251,191
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Atlas Venture Life Science Advisors, LLC
6,875,698 sh
 
$149,684
BVF Inc Il
4,692,604 sh
553,846 sh
13%
$102,158
$20,666
Price T Rowe Associates Inc /Md/
4,097,712 sh
-1,126,974 sh
-22%
$89,208
-$13,666
Wellington Management Group Llp
3,410,386 sh
-1,624,554 sh
-32%
$74,245
-$24,892
Blackrock Inc.
3,204,682 sh
376,248 sh
13%
$69,767
$14,076
Baker Bros. Advisors Lp
2,879,825 sh
 
$62,694
Redmile Group, LLC
2,876,637 sh
269,507 sh
10%
$62,624
$11,290
Vanguard Group Inc
2,863,177 sh
-11,547 sh
0%
$62,332
$5,728
State Street Corp
2,685,404 sh
-829,034 sh
-24%
$58,461
-$10,738
Avoro Capital Advisors LLC
2,169,230 sh
909,230 sh
72%
$47,224
$22,415
Artal Group S.A.
1,500,000 sh
500,000 sh
50%
$32,655
$12,965
Wasatch Advisors Inc
1,060,561 sh
489,917 sh
86%
$23,088
$11,852
Rock Springs Capital Management Lp
1,046,743 sh
270,864 sh
35%
$22,788
$7,511
Bank Of New York Mellon Corp
1,025,244 sh
582 sh
0%
$22,318
$2,143
Ecor1 Capital, LLC
796,093 sh
796,093 sh
NEW
$17,331
$17,331
Geode Capital Management, LLC
701,222 sh
25,375 sh
4%
$15,265
$1,958
Deer Management Co. LLC
615,895 sh
 
$13,408
JPMorgan Chase & Co
561,872 sh
-41,506 sh
-7%
$12,232
$352
Candriam Luxembourg S.C.A.
549,618 sh
79,758 sh
17%
$11,966
$2,715
Pictet Asset Management SA
482,001 sh
-164,074 sh
-25%
$10,494
-$2,227

Data imported from Kymera Therapeutics Inc. SEC filings. Check original filings before making any investment decision.